Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The SPERA trial is designed to 1. provide satraplatin to physicians with patients who have
hormone refractory prostate cancer (HRPC) which has progressed following unlimited cytotoxic
chemotherapy regimens for metastatic disease and 2. to evaluate the safety of oral
satraplatin in this patient population.